Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Is enasidenib plus azacitidine better than with azacitidine alone for AML patien...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
PET-Directed therapy for early-stage diffuse large B-cell lymphoma ( Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA )
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible newly...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switz...
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019
Prognostic impact of chromosomal abnormalities and copy number alterations in B-...
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14 ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
19 Dec 2019
Long-term outcomes of subjects with EBV driven PTLD following solid organ or all...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel ( Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX-35...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, US...
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
19 Dec 2019
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negativ...
Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )
19 Dec 2019
The challenges of treating breast cancer in Brazil
Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )
19 Dec 2019
The importance of central pathology pCR review in an international multicenter n...
Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
19 Dec 2019